Department of Health written question – answered at on 22 October 2014.
To ask the Secretary of State for Health, what assessment he has made of the potential effect of the sale of the Bexsero form of meningococcal group B vaccine to GlaxoSmithKline on (a) his Department's negotiations with Novartis on a price for the vaccine and (b) the roll out of that vaccine.
As the commercial negotiations with Novartis are confidential and this includes any assessments made to inform the negotiations, it is not possible to provide the information requested.
Yes0 people think so
No1 person thinks not
Would you like to ask a question like this yourself? Use our Freedom of Information site.